JP2023531251A - 抗ｃｄ２抗体 - Google Patents

抗ｃｄ２抗体 Download PDF

Info

Publication number
JP2023531251A
JP2023531251A JP2022580094A JP2022580094A JP2023531251A JP 2023531251 A JP2023531251 A JP 2023531251A JP 2022580094 A JP2022580094 A JP 2022580094A JP 2022580094 A JP2022580094 A JP 2022580094A JP 2023531251 A JP2023531251 A JP 2023531251A
Authority
JP
Japan
Prior art keywords
antibody
antigen
subject
binding
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022580094A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531251A5 (https=
Inventor
ベルグランド デビッド
ベルグランド エリック
セルバーグ フェリックス
バインダー クリスチャン
Original Assignee
ゼラリオン マルタ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゼラリオン マルタ リミテッド filed Critical ゼラリオン マルタ リミテッド
Publication of JP2023531251A publication Critical patent/JP2023531251A/ja
Publication of JP2023531251A5 publication Critical patent/JP2023531251A5/ja
Priority to JP2025252172A priority Critical patent/JP2026053445A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022580094A 2020-06-23 2021-06-22 抗ｃｄ２抗体 Pending JP2023531251A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025252172A JP2026053445A (ja) 2020-06-23 2025-12-16 抗ｃｄ２抗体

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063042844P 2020-06-23 2020-06-23
US63/042,844 2020-06-23
US202163135381P 2021-01-08 2021-01-08
US63/135,381 2021-01-08
US202163182095P 2021-04-30 2021-04-30
US63/182,095 2021-04-30
PCT/EP2021/066989 WO2021259927A2 (en) 2020-06-23 2021-06-22 Anti-cd2 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025252172A Division JP2026053445A (ja) 2020-06-23 2025-12-16 抗ｃｄ２抗体

Publications (2)

Publication Number Publication Date
JP2023531251A true JP2023531251A (ja) 2023-07-21
JP2023531251A5 JP2023531251A5 (https=) 2024-07-16

Family

ID=76730545

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022580094A Pending JP2023531251A (ja) 2020-06-23 2021-06-22 抗ｃｄ２抗体
JP2025252172A Pending JP2026053445A (ja) 2020-06-23 2025-12-16 抗ｃｄ２抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025252172A Pending JP2026053445A (ja) 2020-06-23 2025-12-16 抗ｃｄ２抗体

Country Status (9)

Country Link
US (2) US20230365687A1 (https=)
EP (1) EP4168035A2 (https=)
JP (2) JP2023531251A (https=)
CN (1) CN116322766A (https=)
AU (1) AU2021298111A1 (https=)
BR (1) BR112022026429A2 (https=)
CA (1) CA3188130A1 (https=)
MX (1) MX2022016039A (https=)
WO (1) WO2021259927A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023224980A1 (en) * 2022-05-17 2023-11-23 The Uab Research Foundation Methods and compositions for treating or preventing inflammatory skin disorders
US20240228620A1 (en) 2022-10-06 2024-07-11 Bicara Therapeutics Inc. Multispecific proteins and related methods
WO2024079046A1 (en) * 2022-10-10 2024-04-18 Zelarion Malta Limited Anti-cd2 antibodies for type 1 diabetes
EP4673468A1 (en) 2023-03-01 2026-01-07 Zelarion Malta Limited Anti-cd2 antibodies for amyotrophic lateral sclerosis
KR20260016903A (ko) * 2023-05-30 2026-02-04 임노테크 쥐엠비에이치 항-cd2 단일 도메인 항체, 암 진단 및/또는 치료용 약학적 조성물 및 키트
WO2025207763A1 (en) * 2024-03-27 2025-10-02 Zelarion Malta Limited Method and composition for inducing tolerance of transplanted organ or tissue
WO2026052700A1 (en) 2024-09-05 2026-03-12 Zelarion Malta Limited Anti-cd2 antibodies for amyotrophic lateral sclerosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010159286A (ja) * 2002-09-05 2010-07-22 Medimmune Llc Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法
WO2019108860A1 (en) * 2017-11-29 2019-06-06 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd2+ cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2327980T3 (es) * 1996-08-16 2009-11-05 Biotransplant, Inc Anticuerpo lo- d2a y sus usos para inhibir la activacion y la proli feracion de celulas t.
US6692743B1 (en) * 1998-05-08 2004-02-17 Universite Catholique De Louvain Apoptosis of naive human NK cells by crosslinking of their FcγRIIIa molecules with a rat IgG2b (LO-CD2a/BTI-322) or its IgG1 humanized monoclonal antibody
AU2002250236A1 (en) * 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
JP2013540731A (ja) * 2010-09-08 2013-11-07 イェダ リサーチ アンド デベロップメント カンパニー リミテッド 安定かつ長期間の生着のための免疫抑制薬物組合せ

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010159286A (ja) * 2002-09-05 2010-07-22 Medimmune Llc Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法
WO2019108860A1 (en) * 2017-11-29 2019-06-06 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd2+ cells

Also Published As

Publication number Publication date
MX2022016039A (es) 2023-05-04
WO2021259927A3 (en) 2022-03-17
BR112022026429A2 (pt) 2023-04-18
JP2026053445A (ja) 2026-03-25
WO2021259927A2 (en) 2021-12-30
US20240270845A1 (en) 2024-08-15
AU2021298111A1 (en) 2023-02-09
US20230365687A1 (en) 2023-11-16
CA3188130A1 (en) 2021-12-30
EP4168035A2 (en) 2023-04-26
CN116322766A (zh) 2023-06-23

Similar Documents

Publication Publication Date Title
US20240270845A1 (en) Anti-cd2 antibodies
JP6013733B2 (ja) Ｃｄ３７免疫治療薬および二機能性化学療法薬とのその組合せ
RS66218B1 (sr) Anti-cd154 antitela i njihove upotrebe
US20240287198A1 (en) Anti-cd40 antibodies for use in prevention of graft rejection
JP2018522541A (ja) 抗ｃｌｌ−１抗体及び使用方法
CN116903727A (zh) 具有和不具有t细胞抑制蛋白的april和baff抑制性免疫调节蛋白及其使用方法
TW201831513A (zh) 結合物件(一)
EP3606959A2 (en) Anti-icos agonist antibodies and uses thereof
TW201841940A (zh) 抗lag3抗體
TW201636366A (zh) 抗ＣＤ７９ｂ抗體及其使用方法
CN102271708A (zh) Cd37免疫治疗联合疗法及其用途
WO2023126445A1 (en) Anti-cd2 antibodies
JP2025037921A (ja) 抗ｍｅｒｔｋ抗体及びその使用方法
WO2020078454A1 (en) Method of modulating autoimmunity by disrupting cis‐ligand binding of siglec type antigens
KR20180037984A (ko) 개선된 결합 특징, 기능적 특징 및 안전성 특징을 구비한 항-cd154 항체 및 인간 면역요법에서의 용도
EP4438054A2 (en) Methods and uses of variant icos ligand (icosl) fusion proteins
US20240358758A1 (en) Methods for treatment of autoimmune diseases
EP3498293A1 (en) Treatment of monogenic diseases with an anti-cd45rc antibody
WO2021129775A1 (zh) 抗ctla-4单克隆抗体及其制备方法与应用
US11993657B2 (en) Bifunctional molecules for treatment of immune disorders
TW202311293A (zh) 免疫療法之組合及其用途
US20260070999A1 (en) Methods of treating autoimmune disorders using multimeric anti-cd38/anti-cd3 antibodies
JP2026513936A (ja) 自己免疫疾患の処置のための方法
HK40116747A (en) Methods and uses of variant icos ligand (icosl) fusion proteins
KR20260010766A (ko) 마스킹된 인터루킨 12를 포함하는 다기능성 분자 및 이의 사용 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240621

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250819

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260120